Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.69 |
| ▸ | PDE6D | O43924 | 1/20 | 0.69 |
| ▸ | PDE8A | O60658 | 1/20 | 0.69 |
| ▸ | PDE5A | O76074 | 1/20 | 0.69 |
| ▸ | PDE9A | O76083 | 1/20 | 0.69 |
| ▸ | PDE8B | O95263 | 1/20 | 0.69 |
| ▸ | PDE6A | P16499 | 1/20 | 0.69 |
| ▸ | PDE6G | P18545 | 1/20 | 0.69 |
| ▸ | PDE4A | P27815 | 1/20 | 0.69 |
| ▸ | PDE6B | P35913 | 1/20 | 0.69 |
| ▸ | PDE6C | P51160 | 1/20 | 0.69 |
| ▸ | PDE1A | P54750 | 1/20 | 0.69 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.69 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.69 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.69 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.69 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.69 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273078 | 1.00 | PDE2A (0.69) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL7269656 | 0.81 | PDE2A (1.00) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL31377420 | 0.81 | PARP1 (0.57) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL3495517 | 0.78 | GRIA1 (0.61) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL8110811 | 0.78 | GRIA1 (0.61) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL25822706 | 0.78 | GRIA1 (0.61) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL8111947 | 0.78 | GRIN2D (0.69) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL30973146 | 0.78 | GRIA1 (0.61) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL30809703 | 0.75 | PDE2A (0.67) | PDE2APDE6DPDE8APDE5APDE9A | |
| SCHEMBL8566230 | 0.75 | PDE2A (0.67) | PDE2APDE6DPDE8APDE5APDE9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2010-05-27 | — | — | US | claimed |
| EP-2155750-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | Mutabilis SA (FR) | 2010-02-24 | — | — | EP | claimed |
| WO-2008117225-A2 | NEW IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | MUTABILIS SA (FR) | 2008-10-02 | — | — | WO | claimed |
| EP-1972629-A1 | New imidazolo-heteroaryl derivatives with antibacterial properties | Mutabilis SA (FR) | 2008-09-24 | — | — | EP | claimed |
| EP-0691970-B1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AG (DE) | 1998-11-11 | — | — | EP | claimed |
| EP-0691970-A1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-17 | — | — | EP | claimed |
| WO-1994022865-A1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | claimed |
| EP-3240789-B1 | NEW IMIDAZO[1,2-A]QUINOXALINES AND DERIVATES THEREOF FOR THE TREATMENT OF CANCER | UNIV MONTPELLIER (FR) | 2020-07-29 | — | — | EP | disclosed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | AXLR, SATT DU LANGUEDOC ROUSSILLON (FR) | 2018-01-18 | — | — | US | disclosed |
| EP-2114948-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| EP-2114948-B1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBVIE INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8513250-B2 | Imidazolo-heteroaryl derivatives with antibacterial properties | LABORATOIRE BIODIM (FR) | 2013-08-20 | — | — | US | disclosed |
| EP-0708778-B1 | IMIDAZO[1,2-A]PYRAZIN-4-ONE DERIVATIVES FOR USE AS AMPA AND NMDA RECEPTOR ANTAGONISTS | RHONE POULENC RORER SA (FR) | 1997-02-05 | — | — | EP | disclosed |
| EP-0743945-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-11-27 | — | — | EP | disclosed |
| EP-0743945-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1996-11-27 | — | — | EP | disclosed |
| EP-0691970-A1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-17 | — | — | EP | disclosed |
| WO-1995021842-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-08-17 | — | — | WO | disclosed |
| WO-1995021842-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-08-17 | — | — | WO | disclosed |
| WO-1994022865-A1 | IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130489-A1 | IMIDAZOLO-HETEROARYL DERIVATIVES WITH ANTIBACTERIAL PROPERTIES | DLAT, DLST, DNTT | PDE2A 2958/4885PDE6D 4410/4885PDE8A 3684/4885 |
| US-20180016278-A1 | Imidazo[1,2-a]quinoxalines and Derivatives Thereof for the Treatment of Cancer | NQO1, NQO2, ABL1 | PDE2A 1534/4885PDE6D 2550/4885PDE8A 3763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.